Loading…
Loading…
EQUITY / NASDAQ · XNCM
PDS Biotechnology Corporation
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.7485 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.7485 USD · Volume 3,656,797
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -6,496,734 USD | — | — |
| Net income | -9,750,575 USD | — | — |
| Cash and cash equivalents | 5,596,254 USD | — | — |
| Total liabilities | 12,386,952 USD | — | — |
| Total equity | -3,579,739 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end10/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 5,596,254 USD | — | — | 26,711,969 USD | 26,711,969 USD | — | — | — |
| Net incomeIncome statement | -9,750,575 USD | -17,099,631 USD | -7,349,056 USD | — | -7,562,919 USD | -34,495,505 USD | -9,009,411 USD | -26,932,586 USD |
| Operating profitIncome statement | -6,496,734 USD | -13,017,821 USD | — | — | — | -31,543,959 USD | — | -24,869,251 USD |
| Total assetsBalance sheet | 8,807,213 USD | — | — | 30,494,083 USD | 30,494,083 USD | — | — | — |
| Total equityBalance sheet | -3,579,739 USD | — | 3,892,643 USD | 9,251,833 USD | 9,251,833 USD | — | 9,453,510 USD | — |
| Total liabilitiesBalance sheet | 12,386,952 USD | — | — | 21,242,250 USD | 21,242,250 USD | — | — | — |
| Financing cash flowCash flow statement | — | -13,951,560 USD | — | — | — | 12,774,390 USD | — | 8,558,488 USD |
| Operating cash flowCash flow statement | — | -7,164,155 USD | — | — | — | -27,752,012 USD | — | -24,049,427 USD |
| Capital expendituresCash flow statement | — | — | — | — | — | 0 USD | — | 0 USD |
| Investing cash flowCash flow statement | — | — | — | — | — | 0 USD | — | 0 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/13/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.